Results 211 to 220 of about 55,423 (289)

Deficient Mismatch Repair and Microsatellite Instability in Solid Tumors. [PDF]

Int J Mol Sci
Awosika JA, Gulley JL, Pastor DM.
europepmc   +1 more source

Pan‐cancer multi‐omics reveals DCAF7 as an immune‐modulating prognostic driver and Wnt/β‐catenin activator in hepatocellular carcinoma

Clinical and Translational Medicine, Volume 16, Issue 1, January 2026.
DCAF7 is up‐regulated in various tumours and correlates with poor prognosis, particularly in LIHC. High DCAF7 expression is linked to CD4+ T cell infiltration, up‐regulation of immune checkpoint genes and increased tumour mutational burden, suggesting a role in tumour immune escape.
Ruina Luan, Hanbin Lin, Xin Zhao, Jianpeng Li, Maohe Chen, Shiping Luo, Xinjian Lin   +6 more
wiley   +1 more source

Mismatch Repair Deficiency in Gliomas: A Rare Insight into Microsatellite Instability and Its Diagnostic Implications. [PDF]

Asian J Neurosurg
Rajendiran I, Ahluwalia C, Shankar KB, Arora S, Ahuja S.   +4 more
europepmc   +1 more source

Baseline multi‐omics signatures could predict therapeutic response to neoadjuvant anti‐PD‐1 immunochemotherapy in non‐small‐cell lung cancer

Clinical and Translational Medicine, Volume 16, Issue 1, January 2026.
Overview of study design. Metagenomic and plasma/fecal metabolomic studies were performed in 44 NSCLC patients who underwent neoadjuvant tislelizumab therapy plus platinum ‐ based doublet chemotherapy. Abstract Background Neoadjuvant anti‐programmed cell death 1 (PD‐1) immunochemotherapy has shown promising efficiency in the treatment of early‐stage ...
Ailing Cao, Yaobin Lin, Shaoxing Guan, Youhao Chen, Wenyu Zhai, Yuheng Zhou, Shoucheng Feng, Yanping Guan, Yiyu Zhang, Min Huang, Xueding Wang, Hao Long   +11 more
wiley   +1 more source

Successful treatment with pembrolizumab for microsatellite instability-high thymic carcinoma: A case report. [PDF]

Respir Med Case Rep
Sakamori Y, Hamada K, Kawachi H, Yamoto M, Fukao A, Terashita S, Watanabe K, Ikeue T, Sugita T.   +8 more
europepmc   +1 more source

Multi‐omics analysis identifies PUS7 as an immune modulator driving NETs‐mediated macrophage polarization in pancreatic cancer

Clinical and Translational Medicine, Volume 16, Issue 1, January 2026.
PUS7 reshapes the PDAC immune landscape primarily by inducing NETs, which drive macrophage polarization from M1 to M2, fostering immune suppression and tumour progression. The inhibitory effects of S428‐1145 and DNase I on pancreatic cancer are mediated through blocking the PUS7/NETs/M2 macrophage pathway.
Jike Fang, Shiye Ruan, Yajie Wang, Yue Chen, Fuxin Huang, Zhongyan Zhang, Chuanzhao Zhang, Baohua Hou, Shanzhou Huang   +8 more
wiley   +1 more source

Integrating nutritional and inflammatory biomarkers in colorectal cancer management: Implications of microsatellite instability status. [PDF]

World J Gastrointest Surg
Xie RX, Xing YX, Sun NZ.
europepmc   +1 more source

Targeting neutrophil‐driven immunosuppression: A strategy to overcome immune checkpoint inhibitor resistance

Clinical and Translational Medicine, Volume 16, Issue 1, January 2026.
TANs drive ICI resistance via antitumour immune remodelling, angiogenesis promotion, and elevation of tumour mutation burden Neutrophil biomarkers (e.g., NLR, TAN abundance) show strong predictive value for ICI response and prognosis. Targeting TAN recruitment, polarization, function and NETosis represents a promising strategy to overcome ICI ...
Ying Ning, Ke Lei, Xinyan Gao, Yan Kong, Yuping Shan, Tian Tian, Zhumei Cui, He Ren   +7 more
wiley   +1 more source

Microsatellite Instability in the Tumor Microenvironment: The Role of Inflammation and the Microbiome. [PDF]

Cancer Med
Vargas-Castellanos E, Rincón-Riveros A.
europepmc   +1 more source

Synthetic lethality in cancer therapy: Mechanisms, models and clinical translation for overcoming therapeutic resistance

Clinical and Translational Medicine, Volume 16, Issue 1, January 2026.
Application of synthetic lethality screening in drug resistance models. Abstract Background and Rationale Synthetic lethality (SL)‐based strategies hold significant promise for overcoming therapeutic resistance, a critical bottleneck in cancer treatment where cancer cells evade anticancer therapies, leading to diminished efficacy or treatment failure ...
Junyan Li, Liyuan Zhang, Yan Shang, Juan Liu, Hailong Zhao   +4 more
wiley   +1 more source